Profile data is unavailable for this security.
About the company
Spago Nanomedical publ AB, formerly Spago Imaging publ AB, is a Sweden-based biotechnology company. It specialized in the areas of contrast agents and nanoscale life science research. The Company is involved in three projects: Spago Pix, a nanomaterial developed for use as a cancer selective contrast agent for Magnetic Resonance Imaging (MRI); the therapeutic project Tumorad, using nanoparticles loaded with radionuclides for selective treatment of cancers, which are unsuitable for surgery or external radiation; and Archaea Platin, aimed at delivering of chemotherapeutic substance cisplatin selectively to tumors in order to reduce side effects on healthy tissue. The Company's technology comprises a technology platform IonXgel, which is a nano-sized biocompatible material consisting of polar polymers; a protein-based drug delivery platform, ProtRc; and 3PEG, a platform which enables attachment of polyethylene glycol (PEG) derivatives to small molecules (PEGylation).
- Revenue in SEK (TTM)1.81m
- Net income in SEK-35.86m
- Incorporated1999
- Employees12.00
- LocationSpago Nanomedical AB (publ)Scheelevagen 22LUND 223 63SwedenSWE
- Phone+46 4681188
- Websitehttps://spagonanomedical.se/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Orphazyme A/S | 0.00 | -17.38m | 47.69m | 1.00 | -- | 1.95 | -- | -- | -325.75 | -325.75 | 0.00 | 455.65 | 0.00 | -- | -- | 0.00 | -42.26 | -76.08 | -50.77 | -105.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.00 | -- | -- | -- |
Combigene AB | 1.91m | -36.52m | 49.90m | 10.00 | -- | 0.5269 | -- | 26.07 | -1.84 | -1.84 | 0.0967 | 4.78 | 0.0161 | -- | 3.71 | 239,265.00 | -30.66 | -13.00 | -32.33 | -14.58 | -- | -- | -1,908.16 | -58.77 | -- | -- | 0.00 | -- | -79.23 | 268.58 | -479.27 | -- | -24.02 | -- |
Nidhogg Resources Holding AB (publ) | 32.00k | -4.21m | 54.09m | 3.00 | -- | 59.38 | -- | 1,690.42 | -0.0021 | -0.0021 | 0.00005 | 0.0005 | 0.0087 | -- | 0.0128 | 10,666.67 | -114.92 | -70.56 | -204.32 | -82.81 | -25,093.75 | -- | -13,156.25 | -- | -- | -- | -- | -- | -- | -- | 77.06 | -- | -- | -- |
ViroGates A/S | 8.08m | -20.00m | 56.94m | 10.00 | -- | 4.01 | -- | 7.05 | -5.78 | -5.78 | 1.18 | 1.45 | 0.3331 | 0.3869 | 6.80 | 530,700.00 | -82.42 | -46.58 | -89.49 | -52.09 | 69.49 | 77.91 | -247.47 | -238.01 | 8.60 | -19.26 | 0.3626 | -- | -45.01 | 10.98 | -25.40 | -- | -- | -- |
Modus Therapeutics Holding AB | 0.00 | -15.01m | 59.84m | 2.00 | -- | 6.08 | -- | -- | -0.5898 | -0.5898 | 0.00 | 0.2738 | 0.00 | -- | -- | 0.00 | -165.57 | -141.06 | -- | -278.44 | -- | -- | -- | -- | -- | -18.39 | 0.00 | -- | -- | -- | 2.31 | -- | -- | -- |
Ultimovacs ASA | 0.00 | -174.02m | 61.19m | 23.00 | -- | 0.2899 | -- | -- | -5.21 | -5.21 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -51.97 | -28.80 | -57.15 | -31.12 | -- | -- | -- | -- | -- | -114.19 | 0.0137 | -- | -- | -- | -12.78 | -- | -45.35 | -- |
Abera Bioscience AB | 0.00 | -7.63m | 62.48m | 6.00 | -- | 7.10 | -- | -- | -0.5213 | -0.5213 | 0.00 | 0.5733 | 0.00 | -- | -- | 0.00 | -73.37 | -79.42 | -98.59 | -96.10 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 13.74 | -- | -- | -- |
PCI Biotech Holding ASA | 5.82m | -15.53m | 64.79m | 7.00 | -- | 2.09 | -- | 11.13 | -0.4287 | -0.4287 | 0.1607 | 0.8548 | 0.1334 | -- | 0.9365 | 857,000.00 | -35.59 | -36.44 | -40.42 | -40.14 | -- | -- | -266.74 | -1,055.43 | -- | -- | 0.0147 | -- | -37.05 | -20.78 | 63.13 | -- | -- | -- |
Chosa Oncology AB | 5.00k | -8.58m | 76.62m | -- | -- | 3.54 | -- | 15,323.94 | -0.1745 | -0.1745 | 0.00009 | 0.3054 | 0.0002 | -- | 0.0009 | -- | -28.72 | -51.96 | -31.51 | -61.92 | -- | -- | -171,540.00 | -708.47 | -- | -28.22 | 0.00 | -- | -98.21 | -- | 28.33 | -- | -- | -- |
Spago Nanomedical AB (publ) | 1.81m | -35.86m | 80.78m | 12.00 | -- | 1.62 | -- | 44.61 | -0.2614 | -0.2614 | 0.0106 | 0.1436 | 0.0386 | -- | 2.43 | 139,307.70 | -76.46 | -20.19 | -86.74 | -20.97 | -97.96 | -- | -1,980.40 | -4,853.45 | -- | -- | 0.00 | -- | 14.14 | -- | -7.72 | -- | -- | -- |
Sprint Bioscience AB | 85.01m | 14.72m | 81.69m | 36.00 | 5.55 | 4.37 | 5.28 | 0.9609 | 0.2108 | 0.2108 | 1.22 | 0.2677 | 2.38 | -- | 13.18 | 3,036,214.00 | 41.28 | -71.22 | 128.58 | -113.71 | 76.51 | 62.75 | 17.31 | -110.22 | -- | -- | 0.00 | -- | 60,725.30 | 22.99 | 99.27 | -- | -26.02 | -- |
Dextech Medical AB | 0.00 | -4.71m | 86.88m | 1.00 | -- | 2.93 | -- | -- | -0.2546 | -0.2546 | 0.00 | 1.60 | 0.00 | -- | -- | -- | -14.35 | -23.30 | -14.73 | -23.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.52 | -- | -- | -- |
Coegin Pharma AB | 0.00 | -26.00m | 90.32m | 1.00 | -- | 4.19 | -- | -- | -2.25 | -2.25 | 0.00 | 1.06 | 0.00 | -- | -- | -- | -111.12 | -122.02 | -119.99 | -154.70 | -- | -- | -- | -28,466.75 | -- | -55.53 | 0.00 | -- | -- | -- | 20.60 | -- | -- | -- |
Klaria Pharma Holding AB (publ) | -6.53m | -18.21m | 94.98m | 5.00 | -- | 4.57 | -- | -- | -0.1594 | -0.4121 | -0.0605 | 0.1603 | -0.0864 | -- | -- | -1,305,600.00 | -24.10 | -37.28 | -44.74 | -51.56 | -- | -- | -- | -2,077.34 | -- | -0.439 | 0.00 | -- | -100.00 | -- | 71.17 | -- | -- | -- |
Prolight Diagnostics AB (publ) | 0.00 | -140.00m | 118.86m | 16.00 | -- | 0.8134 | -- | -- | -0.3853 | -0.3853 | 0.00 | 0.2447 | 0.00 | -- | -- | 0.00 | -66.82 | -- | -89.89 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -13.84 | -- |
Holder | Shares | % Held |
---|---|---|
FCG Fonder ABas of 30 Aug 2024 | 39.70k | 0.01% |